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Abstract
Chlamydiae are obligatory intracellular parasites which are responsible for various acute and chronic diseases in animals
and humans. The outer membrane of the chlamydial cell wall contains a truncated lipopolysaccharide (LPS) antigen, which
harbors a group-specific epitope being composed of a trisaccharide of 3-deoxy-D-manno-oct-2-ulosonic (Kdo) residues of the
sequence K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo. The chemical structure was established using LPS of recombinant
Escherichia coli and Salmonella enterica strains after transformation with a plasmid carrying the gene encoding the
multifunctional chlamydial Kdo transferase. Oligosaccharides containing the Kdo region attached to the glucosamine
backbone of the lipid A domain have been isolated or prepared by chemical synthesis, converted into neoglycoproteins and
their antigenic properties with respect to the definition of cross-reactive and chlamydia-specific epitopes have been
determined. The low endotoxic activity of chlamydial LPS is related to the unique structural features of the lipid A, which is
highly hydrophobic due to the presence of unusual, long-chain fatty acids. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
This review will concentrate on the structure, anti-
genic properties, biosynthesis and biological func-
tions of carbohydrate antigens located in the outer
membrane of Chlamydia. While it is not intended to
give an in-depth view for chlamydiologists in partic-
ular, it should give the general reader insight into the
fascinating immunobiology of an intracellular bacte-
rial parasite.
Chlamydiae are responsible for various acute or
chronic diseases in animals and humans [1], which
are of increasing biomedical importance viewed
from the impact, scope and frequency of chlamydial
infections [2]. Brie£y, Chlamydia trachomatis strains
a¡ect several hundred millions of individuals in de-
veloping countries causing trachoma which eventu-
ally may lead to blindness. In industrialized coun-
tries, C. trachomatis infection is the most prevalent
sexually transmitted disease (STD). Furthermore, the
role of another chlamydial species, C. pneumoniae, in
the context of coronary artery diseases demands
highest attention and may turn out to be one of
the most important ¢ndings in infectious disease bi-
ology in the last decade.
The present state of Chlamydia research is charac-
terized by manifold activities to provide the molec-
ular and genetic basis in order to understand the
various steps in the infectious cycle starting from
adherence of Chlamydia to host cell membranes,
phagocytosis, structural and morphological changes
within the phagosome, and further di¡erentiation
processes leading to infectious particles or persisting
forms. In continuation of previous reviews on this
topic [3,4], this chapter will give a short description
of the taxonomy, clinical relevance and microbiology
of chlamydiae followed by the most important devel-
opments achieved in the immunobiology and anti-
genic properties of chlamydial lipopolysaccharide,
one of the major antigenic sites in the cell wall of
Chlamydia.
2. Taxonomy
Chlamydiae are bacteria of small dimensions (200^
300 nm in size) occurring as strictly intracellular par-
asites in human and animal cells. Due to their unique
developmental cycle (see below) they have been
placed in the separate order (Chlamydiales) compris-
ing one family (Chlamydiaceae) ^ with only one ge-
nus ^ Chlamydia (for a recent reclassi¢cation see [5]).
Up to now, four di¡erent species of Chlamydia have
been identi¢ed: C. trachomatis, C. pneumoniae, C.
psittaci and C. pecorum (Table 1). Although the spe-
cies show a very low homology by DNA/DNA hy-
bridization studies [6], the homology of their 16S
rRNA exceeds 95% indicating a common origin (Ta-
ble 2). Whereas only one serovar has been identi¢ed
thus far for C. pneumoniae, 18 have been found for
C. trachomatis and several serovars have been de-
scribed for C. psittaci [7] and C. pecorum [8]. Di¡er-
entiation of serovars has been based on the major
outer membrane protein (omp-1) by using monoclo-
nal antibodies or PCR-ampli¢cation of the corre-
sponding genes [9^11].
3. Clinical manifestations and epidemiology
For a general review on chlamydial infections, the
reader is referred to Ref [12]. Brie£y, C. psittaci plays
a role as a pathogen mainly in veterinary medicine
[7]. The species has been detected in sheep, cattle,
cats, and most frequently in birds, which may trans-
mit the organism to humans leading to severe atyp-
ical pneumonia known as ornithosis or psittacosis.
Occasionally, infections by C. psittaci have been ob-
served in employees of poultry industries.
C. trachomatis serovars A, B, Ba and C are re-
sponsible for endemic trachoma cases in Africa and
Asia, which at the ¢nal stage of the ocular infection
lead to blindness. Estimated numbers for C. tracho-
matis infections range between 300^500 million
worldwide. Furthermore, C. trachomatis serotypes
Ba, E^K are implicated in a substantial percentage
of sexually-transmitted urogenital infections. In
women, chlamydiae are prone to invade the cervix
ascending the endometrium and Fallopian tubes,
causing salpingitis, endometritis or cervicitis, which
eventually may lead to infertility. Furthermore, the
infectious agent may be passed on the newborn, lead-
ing to neonatal conjunctivitis as well as infant pneu-
monia, whereas adults may contract inclusion con-
junctivitis. In men, infections by C. trachomatis may
be responsible for urethritis, epididymitis and per-
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haps prostatitis. The serovars L1^L3 have been
known for a long time to cause lymphogranuloma
venereum (LGV). Moreover, reactive arthritis may
develop following sexually-acquired C. trachomatis
infections [13,14] and the presence of viable chlamy-
diae in joints of patients with Reiter’s syndrome has
been shown [15].
C. pneumoniae, ¢rst isolated in 1986, has been es-
tablished as the third chlamydial species in 1989. The
species comprises one serovar, designated TWAR ac-
cording to two laboratory isolates [16,17]. Infection
by C. pneumoniae is prevalent among children be-
tween 5 to 14 years of age, in younger children, anti-
bodies against chlamydiae are much less frequently
observed. In general, C. pneumoniae causes roughly
10% of community-acquired pneumonia and 5% of
bronchitis cases. Seroepidemiological studies reveal a
high incidence of C. pneumoniae-speci¢c antibodies
indicating that between 50^75% (percentage increases
with age) of the population has had contact with the
bacterium. Notably, the seroprevalence is signi¢-
cantly higher in men than in women.
Interest in the pathophysiology of chlamydial in-
fections has been boosted by the report of Saikku
and colleagues [18] of a serological association be-
tween C. pneumoniae infection and coronary artery
disease and atherosclerosis. The initial serological
study performed in Finland has been substantiated
by other seroepidemiological studies in the United
States, Europe and Asia [19]. Following the ¢nding
of a serological association of C. pneumoniae with
cardiovascular diseases, C. pneumoniae particles
were detected in foam cells in atherosclerotic lesions
by electron microscopy, immunocytochemical stain-
ing and PCR testing of chlamydial DNA, respec-
tively [20^22]. In addition to results obtained from
various murine and rabbit model studies, the bacteria
have been found in the coronary arteries of young
adults [23], and viable chlamydiae have been isolated
from atherosclerotic plaques [24,25]. Whereas a caus-
ative function of C. pneumoniae for the onset or ag-
gravation of atherosclerotic processes is still a matter
of controversial debate, the role of these microorgan-
isms most likely will exceed that of ‘innocent by-
standers’ as they have sometimes been alluded to.
The consequences of chronic infections [26,27] with
concomitant in£ammatory and Th2-type responses
[28] warrant further concise studies in the ¢eld with
Table 1
Characterization of chlamydial species
Family Chlamydiaceae
Genus Chlamydia
Species C. trachomatis C. pneumoniae C. psittaci C. pecorum
Serovars A, B, Ba, C^K, L1^L3 1 (TWAR) 6 10 3
Morphology of EB Coccoid Pear-shaped Round Round
Prevalent hosts Humans Humans Birds, sheep, cattle, cats Swine, cattle,
sheep
Major diseases in humans Trachoma, conjunctivitis,
LGV, salpingitis,cervicitis,
endometritis, urethritis,
arthritis, Reiters disease,
neonatal pneumonia
Bronchitis,
pneumonia,endocarditis?,
asthma?, arteriosclerosis?
Pneumonia (ornithosis,
psittacosis)
Table 2
DNA^DNA homology (%) between chlamydial species
C. trachomatis C. pneumoniae C. psittaci C. pecorum
C. trachomatis 92 1^7 1^33 1^10
C. pneumoniae 94^96 1^8 10
C. psittaci 14^95 1^20
C. pecorum 88^100
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special emphasis on well-designed studies with Chla-
mydia-e¡ective antibiotics. Ongoing clinical trials
with antibiotics administered to patients with myo-
cardial infarctions have not led to unambiguous con-
clusions yet.
4. Microbiology
Chlamydiae harbor some of the characteristic
components of bacterial cell walls of Gram-negative
bacteria; they lack, however, the presence of a rigid
peptidoglycan layer (although the occurrence of mur-
amic acid has been proved) probably as a conse-
quence of adaptation to the intracellular environ-
ment. Moreover, chlamydiae depend on the bio-
synthetic apparatus of their respective host cells
and deprive them of energy-rich triphosphates, nu-
trients and cofactors.
4.1. Developmental cycle
During infection, chlamydiae undergo a character-
istic unique biphasic life cycle within a period of 48^
72 h [29]. The infection process is initiated by the
attachment of elementary bodies (EBs) to epithelial
cells. Elementary bodies are infectious particles
measuring 200^300 nm in diameter, which display a
three-layered outer membrane (Fig. 1). EBs are quite
resistant to environmental conditions outside the
host cell, making them adapted to cell^cell and
host^host transits. The cell walls of EBs are rigidi¢ed
by major outer membrane protein units being highly
cross-linked via disul¢de bridges [30]. In addition,
the chlamydial major outer membrane protein
omp-1 is a glycoprotein of the high-mannose type,
and manno-oligosaccharides have been found to me-
diate attachment and infectivity of C. trachomatis to
HeLa cells [31]. Meanwhile it has been demonstrated
that human mannose-binding protein is capable to
bind high-mannose structures on the surface of chla-
mydiae and thus may be involved in host defense
mechanisms against chlamydial infections [32].
Heparan sulfate-like glycans being present on the
Fig. 1. Electron microscopy photograph of the elementary body
(EB) from C. trachomatis L2 within a phagosome of a mouse
¢broblast cell. OM, outer membrane of the EB; PM, plasma
membrane of the ¢broblast.
Table 3
Chemical composition of Chlamydia- and Re-LPSa
Constituent Amount (nmol/mg) present in LPS of:
C. trachomatis C. psittaci E. coli Re
Glucosamine 480 (2.0) 513 (2.0) 720 (2.0)
Galactosamine 257 (1.0)
Kdo 715 (3.0) 1190 (4.9) 732 (2.0)
Phosphate 625 (2.6) 578 (2.3) 748 (2.1)
Fatty acids 1185 (4.9) 1190 (4.6) 1955 (5.4)
aMolar ratios in parentheses.
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surface of the host cell [33] have been proposed to
be involved in the adhesion process, but did not
show protective properties when used as inhibitors
of genital chlamydial infections in a mouse model
[34].
Entry of elementary bodies proceeds by host-driv-
en endocytosis. Within a vacuole, elementary bodies
undergo a signi¢cant morphological change into the
larger (0.8^1 Wm in size), metabolically active retic-
ulate bodies (RBs), which are not capable to survive
outside the host. The cell wall of RBs is much less
rigid probably due to reductive opening of the cova-
lent disul¢de cross-linkings allowing for enhanced
metabolic activities and transport of nutrients. By
unknown mechanisms, phagosome^lysosome fusion
is inhibited. Reticulate bodies multiply by binary ¢s-
sion forming microcolonies as so-called inclusion
bodies. Finally, reticulate bodies condense, enhance
the rate of biosynthesis of outer membrane proteins
and reorganize into infectious elementary bodies,
which are released by exocytosis or lysis of the host
cells.
By and large, the signals and mechanisms being
responsible for the interconversion of elementary
bodies and reticulate bodies are unknown. Chlamy-
dial surface antigens, however, appear to be involved
in several steps [35,36]. Deviations from the charac-
teristic developmental stages are known and indicate
an inherent £exibility to di¡erent intracellular condi-
tions. Chlamydiae may exist inside cells in aberrant
forms such as giant reticulate bodies or as persistent,
culture-negative but potentially infectious agents
leading to chronic in£ammatory responses [37]. For
example, the presence of persistent chlamydiae is ac-
companied by increased expression of chlamydial
heat-shock protein hsp-60, which is implicated in a
delayed-type hypersensitivity immune response lead-
ing to ocular or tubal damage. Furthermore, chlamy-
dial hsp-60 has been detected in human atheromas
[38]. In fact, since chlamydial hsp-60 displays several
sequence homologies with the human heat-shock
protein hsp60, autoimmune responses may be trig-
gered [39].
4.2. Outer membrane proteins
The major outer membrane protein (omp-1),which
is similar in molecular mass (V40 kDa) and struc-
ture among the chlamydial species constitutes an im-
portant antigenic site on the surface of chlamydial
cell walls [40]. The protein is composed of four do-
mains carrying species-, subspecies- and serotype-
speci¢c epitopes. Furthermore, seven cysteine resi-
dues of omp-1 seem to be essential to maintain the
structural integrity and rigidity of the cell wall of
elementary bodies by formation of cross-linked com-
plexes via disul¢de bonds. Other, also highly con-
served and cysteine-rich proteins (omp-2) might
have similar functions. All genes of the 15 C. tracho-
matis serovars coding for omp-1 have been cloned,
expressed in E. coli and their sequences have been
determined [41,42]. Protective antibodies against
omp-1 have been described, making omp-1 a target
candidate for vaccine development [43].
4.3. The genus-speci¢c lipopolysaccharide antigen
4.3.1. Chemical structure
The second major antigenic site located in the out-
er membrane is composed of a glycolipid which is
shared by all chlamydial species thus constituting a
genus-speci¢c epitope. It has been known for two
decades that a heat-stable, group-speci¢c epitope re-
sembling structures found in Gram-negative bacteria
is present in chlamydiae [44]. In 1972, the occurrence
of a 2-keto-3-deoxy carbohydrate (not recognized as
Kdo) was described as the immunodominant group
[45]. Subsequently, characteristic components of bac-
terial lipopolysaccharide (LPS) such as D-glucos-
amine, phosphate and long-chain L-hydroxy fatty
acids were isolated from C. trachomatis L2 and a
C. psittaci strain [46,47], adding to the evidence
that the group-speci¢c epitope might be related to
enterobacterial LPS (Table 3). Furthermore, serolog-
ical cross-reactivities between Chlamydia and Acine-
tobacter calcoaceticus had been observed [48^50].
The presence of di¡erent, cross-reactive and speci¢c
antigenic sites within this epitope was shown in an
antiserum raised against the LPS of elementary
bodies of C. trachomatis L2 by means of passive
hemolysis, passive hemolysis inhibition and absorp-
tion experiments [51]. These studies demonstrated
that cross-reactive antibodies could be absorbed
with Salmonella enterica serovar Minnesota Re 595
LPS, whereas the Chlamydia speci¢city remained un-
a¡ected. Moreover, the octulosonic acid occurring as
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a constituent of the epitope was later on identi¢ed as
the acid-labile 3-deoxy-D-manno-oct-2-ulosonic acid
(Kdo), which is a common component of enterobac-
terial LPS [52]. Consequently, mild acid hydrolysis of
chlamydial LPS liberated immunoreactivity of lipid
A, which is not accessible in native LPS [53]. The
data thus clearly provided unambiguous evidence
that the group-speci¢c glycolipid antigen was indeed
a bacterial lipopolysaccharide determinant, the ques-
tion of the molecular basis for the observed Chlamy-
dia speci¢city remained to be solved.
One of the major impairments encountered in
dealing with the structural analysis of chlamydial
components is due to the fact, that chlamydiae may
only be raised in tissue culture or embryonated eggs.
Unfortunately, the construction of genetically de-
¢ned mutants has not been accomplished thus far,
and all vectors which have been employed failed to
transfer recombinant DNA into the microorganism.
Conversely, chlamydial components have been made
amenable to structural analysis following expression
of chlamydial genes in bacterial cells, but still con-
ventional biochemical and analytical techniques have
to be used on very small amounts obtained from
native chlamydial origin.
Decisive progress in the structural elucidation was
achieved by the expression of the Chlamydia-speci¢c
LPS epitope in strains of Escherichia coli K-12 or
Salmonella enterica serovar Minnesota as well as S.
enterica serovar typhimurium [54,55]. The recombi-
nant strains containing the plasmid pFEN207 syn-
thesized, in addition to their parent LPS determi-
nants, a truncated LPS displaying ^ by serology ^
Chlamydia speci¢city. Comparative chemical analyt-
ical data of the parent enterobacterial LPS and the
LPS isolated from the recombinant strains indicated
a di¡erence in the amounts of Kdo, which were 2 for
the parent strains and 2.5 Kdo units for the recombi-
nant strains. Nano and Caldwell [54] had indicated
that their cloned DNA-fragment (6.5 kb) of C. tra-
chomatis DNA might encode a glycosyl transferase.
Subsequently, by using the combined e¡orts of mo-
lecular biology, serology, analytical and synthetic
chemistry, it was shown that the Chlamydia-speci¢c
LPS epitope contains a linear Kdo trisaccharide of
the sequence K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo
[56]. This structure resembles closely LPS-oligosac-
charides from deep-rough type mutant strains, con-
taining the K-Kdo-(2C4)-K-Kdo disaccharide as a
terminal unit [44,52]. The Chlamydia-speci¢c anti-
gen, however, contains a third Kdo residue in a
unique (2C8)-linkage, which by gas chromatogra-
phy^mass spectrometry comparison of the disacchar-
ide octitol derivative obtained from the recombinant
strains with synthetic K- and L-(2C8)-linked disac-
charide derivatives was proved to occur in the K-
anomeric con¢guration [57]. Further structural de-
tails including also the glucosamine disaccharide
backbone were unravelled by degradation of LPS-
oligosaccharides from the recombinant strains.
Thus, following removal of the O-linked fatty acids
of lipid A (nota bene: which still carry the substitu-
tion pattern of the parent bacterial strains), dephos-
phorylation, reduction and de-N-acylation, the pen-
tasaccharide K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo-
(2C6)-L-GlcN-(1C6)-GlcNol was isolated and its
structure was proven by 1H- and 13C-NMR spectros-
copy [58].
By use of di¡erent conditions (de-O-acylation by
hydrazinolysis followed by de-N-acylation with 4 M
KOH) the phosphate groups of the lipid A moiety
could be kept intact (Fig. 2). Separation of these
compounds by high performance anion exchange
chromatography allowed the isolation and structural
characterization of several oligosaccharide bisphos-
phates by 1H-, 31P- and 13C-NMR spectroscopy,
such as the deep-rough mutant type backbone tetra-
saccharide A originating from the parent LPS as well
as the pentasaccharide B [59,60]. Furthermore, from
a recombinant E. coli mutant carrying the kdtA gene
from C. psittaci, additional Kdo-oligosaccharides
such as the pentasaccharide C with the trisaccharide
sequence K-Kdo-(2C4)-K-Kdo-(2C4)-K-Kdo and
the branched hexasaccharide D with a K-Kdo-
(2C8)-[K-Kdo-(2C4)]-K-Kdo-(2C4)-K-Kdo unit
were isolated [61]. It had been noted previously,
Fig. 2. Chemical structures of oligosaccharides isolated by degradation of LPS. A corresponds to the deacylated core oligosaccharide
from the parent LPS occurring in the recombinant strains, B was isolated from E. coli expressing the C. trachomatis Kdo-transferase,
B^D were isolated from recombinant strains containing the Kdo-transferase from C. psittaci.
6
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Fig. 3. Synthetic haptens (R = allyl) and neoglycoconjugates (R = spacer-BSA) representing the genus-speci¢c epitope and part struc-
tures of Chlamydia.
BBADIS 61866 15-9-99
P. Kosma / Biochimica et Biophysica Acta 1455 (1999) 387^402394
that C. psittaci LPS contains on average 4.6 residues
of Kdo per mol of LPS [62]. The occurrence of the K-
(2C4)-linked Kdo trisaccharide (type C) might be
due to an elimination process during the KOH-treat-
ment and does not necessarily indicate a native LPS
structure (H. Brade and O. Holst, personal commu-
nication). Whereas 1-monophosphate derivatives
were obtained by the chemical degradation in addi-
tion to the 1,4P-bisphosphates, treatment of the 1,4P
bisphosphate compounds with alkaline phosphatase
furnished the corresponding 4P-monophosphate de-
rivatives in a selective manner [63].
4.3.2. Antigenic structure
Based on the knowledge achieved for the chemical
structure of the genus-speci¢c epitope, the antigenic
and immunogenic properties were studied in molec-
ular detail employing bacterial antigens as well as
synthetic compounds serving as arti¢cial haptens
and antigens. Numerous Kdo-oligosaccharides have
been prepared as allyl glycosides (Fig. 3), which were
converted into glycopolymers by radical copolymer-
ization of the allyl group with acrylamide [64^67].
Furthermore, addition of cystamine to the allyl
group furnished spacer-elongated derivatives which
were coupled to bovine serum albumin following
activation of the terminal amino group with thio-
phosgene [58]. Antibodies were generated after im-
munization with chlamydiae or Re-mutants or im-
munization of mice with synthetic neoglycoproteins.
Selection of antibodies was performed according
to binding to the immunizing antigen, to LPS as a
solid phase antigen or LPS incorporated into sheep
erythrocytes or liposomes as well as binding to chla-
mydial elementary bodies. By using synthetic hapt-
ens, polyacrylamide copolymers as well as neoglyco-
proteins, epitope speci¢cities of antibodies directed
against enterobacterial LPS and chlamydial LPS
were characterized [68^70]. In inhibition studies
with Chlamydia-speci¢c monoclonal antibodies,
Kdo monosaccharide as well as K-Kdo-(2C4)-K-
Kdo disaccharide ligands were inactive whereas the
K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo trisaccharide
turned out to be a highly e⁄cient inhibitor (Table
4). Binding was not enhanced further by adding parts
of the glucosamine disaccharide backbone to the
epitope [71]. Thus, a clear dissection of cross-reactive
and Chlamydia-speci¢c epitopes became evident,
providing also a basis to understand the previous
serological ¢ndings. Antibodies which had been
raised against the deep rough mutant Salmonella en-
terica serovar Minnesota R595 which recognize K-
Kdo monosaccharide ligands (mAb of type A20) or
Fig. 4. Crystal structure of the synthetic disaccharide disodium
K-Kdo-(2C8)-K-Kdo-(2CO allyl) hemihydrate. The interresi-
due hydrogen bond is indicated (dotted line).
Table 4
Inhibition of the Chlamydia-speci¢c monoclonal antibody S25-23 with arti¢cial glycoconjugates
Inhibitora Inhibition value (WM)
K-Kdo-BSA s 10
K-Kdo-(2C4)-K-Kdo-BSA s 10
K-Kdo-(2C8)-K-Kdo-BSA s 10
K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo-BSA 0.34
K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo-(2C6)-L-GlcNAc-BSA 0.34
K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo-(2C6)-L-GlcNAc-(1C6)-K-GlcNAc-BSA 0.34
aNeoglycoproteins containing the carbohydrate ligands covalently attached via a ^(CH2)3S(CH2)2NHC(NS)NH-spacer group to O-ami-
no groups of lysine of bovine serum albumin (BSA).
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Fig. 5. Chemical structure of the Kdo region and lipid A from the deep rough mutant strain E. coli F515 (upper part) and part struc-
tures of lipid A from C. trachomatis (below).
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K-Kdo-(2C4)-K-Kdo disaccharide units (mAb A25)
were also reactive with the corresponding structural
entities present in chlamydial LPS. Chlamydia spe-
ci¢cities were associated with the K-Kdo-(2C8)-K-
Kdo disaccharide epitope or more pronounced with
the Kdo trisaccharide moiety. The high speci¢city
observed for a disaccharide part structure containing
a highly £exible glycosidic linkage providing addi-
tional conformational freedom is intriguing. In the
crystal structure (Fig. 4) determined for the synthetic
K-Kdo-(2C8)-K-Kdo disaccharide allyl glycoside
(Fig. 3, compound B, R = allyl), an interresidue hy-
drogen bond extending from the terminal carboxyl
group across the glycosidic bond to OH-7 of the
reducing Kdo unit was observed [72]. Meanwhile,
the Fab fragment of a monoclonal antibody recog-
nizing the K-Kdo-(2C8)-K-Kdo disaccharide (mAb
S25-2) has been crystallized (S. Evans, H. Brade,
personal communication). Furthermore, by employ-
ing transfer-NOE experiments of the antibody com-
plex, it was conferred, that out of several low energy
conformations, the bound conformation also in-
cluded a similar arrangement of the two Kdo resi-
dues as seen in the crystal structure [73]. Ongoing
high-¢eld NMR studies with the Kdo-(2C4)-Kdo
disaccharide speci¢c antibodies are expected to give
further insight into these protein-carbohydrate inter-
actions. Unfortunately, similar studies with the tri-
saccharide complex have not been possible due to the
high a⁄nity of the trisaccharide-speci¢c antibody
(mAb S 25-23) to the Kdo-trisaccharide (Fig. 3, com-
pound C, R = allyl). Meanwhile the Kdo trisacchar-
ide has been crystallized as a 1:3 brucine complex (P.
Kosma, M. Walkinshaw, personal communication),
but the crystal structure determination has not yet
been ¢nished.
Based on the results of the antibody studies, a
genus-speci¢c solid phase ELISA test was developed
being used in clinical laboratories for a sensitive de-
termination of IgG, IgM and IgA antibody responses
against chlamydiae [74]. Whereas IgM and IgG anti-
bodies are present during acute infections, elevated
levels of IgG and IgA antibodies may indicate a
chronic state of infection; for example, antibodies
may still be detected after one year following myo-
cardial infarction [75].
Another genus-speci¢c glycolipid antigen has been
reported which has been termed GLXA [76]. GLXA
appears to be di¡erent from chlamydial LPS, but is
poorly de¢ned in chemical and antigenic struc-
ture.
4.3.3. Biosynthesis
The biosynthesis and genetics of bacterial lipopo-
lysaccharide has been summarized in authoritative
reviews [77,78]. In enteric bacteria, Kdo is synthe-
sized from D-arabinose 5-phosphate and phosphoe-
nol pyruvate to give Kdo-8-phosphate. The reaction
is catalyzed by the enzyme 3-deoxy-D-manno-oct-2-
ulosonate-8-phosphate synthase which is encoded
by the gene kdsA. Subsequently the phosphate ester
is hydrolyzed by a phosphatase to generate free Kdo.
Activation of the minor L-pyranose form of Kdo by
a CMP-Kdo synthase (encoded by the kdsB gene)
generates CMP-Kdo [79]. CMP-Kdo is then trans-
ferred in two successive steps by the action of the
Kdo-transferase encoded by the gene kdtA on a pre-
cursor molecule of lipid A (precursor Ia) [80,81] to
provide the ¢rst K-Kdo unit in an K-(2C6)-linkage
to the lipid A precursor, followed by elongation with
the second Kdo to give the K-Kdo-(2C4)-K-Kdo
disaccharide unit. In fact, it has been suggested
that the Kdo transferase from E. coli K-12 is a bi-
functional enzyme [82]. The molecular mass of this
Kdo transferase (V40 kDa) most probably implies
that there is only one catalytic site to accommodate
the two substrates.
In chlamydiae, several genes coding for enzymes
involved in the biosynthesis of the Kdo region have
been cloned and expressed. Although chlamydiae
lack the biosynthetic tools to make ATP, GTP or
UTP, CTP can be synthesized or salvaged from the
host cells. The gene coding for the CTP-synthetase
from C. trachomatis L2 ^ showing a high sequence
identity (42^49%) with known CTP-synthetases ^ has
been cloned and expressed in a CTP-de¢cient E. coli
JF646 strain [83]. The gene kdsA coding for the en-
zyme 3-deoxy-D-manno-oct-2-ulosonate-8-phosphate
synthase, which has been cloned and sequenced in
C. psittaci 6BC, displayed a high degree of similarity
to other known proteins encoded by kdsA [84,85].
Meanwhile, the gene kdsB coding for the CMP-
Kdo synthase has been cloned and sequenced from
C. trachomatis [86].
The Kdo transferase of Chlamydia trachomatis en-
coded by the gene kdtA (formerly termed gseA) has
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been cloned and was able to complement a condi-
tionally lethal kdtA mutant of Escherichia coli
[87,88]. Expression of the chlamydial Kdo transferase
in E. coli K-12 lead to the formation of the genus-
speci¢c Kdo-trisaccharide [89,56], indicating that the
chlamydial enzyme is trifunctional. As a consequence
of the attachment of the third, K-(2C8)-linked Kdo
in recombinant E. coli strains the further addition of
heptose residues is inhibited, leading to the forma-
tion of a truncated LPS of the deep rough mutant
type. The deduced amino acid sequence of the gene
coding for the C. trachomatis Kdo-transferase shares
23% identity (66% similarity) to kdtA of E. coli. Ex-
change of Arg276 (within the identical region) by
Lys, Ile or Ser eliminates the ability to synthesize
the genus-speci¢c epitope [90]. Meanwhile the gene
coding for kdtA of C. psittaci 6BC has also been
cloned, expressed in the deep rough mutant E. coli
F515 and sequenced [91]. Interestingly, the deduced
amino acid sequence of the C. psittaci Kdo transfer-
ase (Mr V46 kDa) shares only 67% overall homol-
ogy compared to C. trachomatis, but the enzyme is
also capable of generating the genus-speci¢c struc-
ture as determined by SDS^PAGE and Western
blot analysis using a Chlamydia-speci¢c LPS-anti-
body. However, in addition to the formation of the
genus-speci¢c K-Kdo-(2C8)-K-Kdo-(2C4)-K-Kdo
trisaccharide, other oligosaccharides were isolated
from degraded LPS of the recombinant strain (cf.
Fig. 2) clearly indicating multifunctional properties
of the C. psittaci Kdo transferase as well. Further-
more, employing the Gram-positive bacterium Cory-
nebacterium glutamicum as expression system ^ lack-
ing the biosynthetic apparatus for LPS assembly ^
unambiguous evidence was provided for the C. pneu-
moniae Kdo transferase to be su⁄cient for the trans-
fer of three Kdo-residues [92]. The formation of the
Kdo-oligosaccharide structures, however, still re-
mains to be shown to take place with the parent
chlamydial lipid A precursor substrate. By using a
temperature gradient gel electrophoresis technique,
nucleotide variations between 15 serovars of C. tra-
chomatis have been analyzed. The pro¢les obtained
indicated a correlation with speci¢c sites of infection
[93].
4.3.4. Lipid A
Since many di¡erent enzymes are involved in the
biosynthetic assembly of lipid A, recombinant tech-
niques which have been used with success for the
determination of the genus-speci¢c LPS-epitope are
not appropriate. Thus structural elucidation has to
rely on classical means by chemical analysis of small
amounts of material isolated from chlamydiae which
have been grown in tissue culture. Preliminary data
obtained previously [46,47] indicated the presence of
¢ve fatty acids per molecule of Lipid A, comprising
only two 3-hydroxy fatty acids of increased chain
length (C20^C22), which were both amide linked.
Meanwhile another milestone in Chlamydia research
has been reached by Qureshi’s report on the structure
of monophosphoryl lipid A moieties isolated from C.
trachomatis serovar F [94]. LPS from elementary
bodies was hydrolyzed to give the monophosphoryl
lipid A derivatives which were converted into methyl
phosphate esters and separated by reverse phase
HPLC. Analysis of the HPLC fractions by matrix-
assisted laser desorption/ionization and liquid secon-
dary ion mass spectrometry revealed a minimum of
20 homologous structures which could be grouped
into two di¡erent series (Fig. 5), three fatty acids
being located at the non-reducing and two of them
at the reducing glucosamine unit. Whereas the full
structural analysis of chlamydial lipid A has not been
accomplished thus far, it is tempting to speculate on
the potential biological e¡ects. The reduced number
of fatty acids (¢ve) compared to E. coli or Salmonella
lipid A carrying six and seven fatty acid residues,
respectively, and the enlarged hydrophobic domain
may endow chlamydial lipid A with reduced endo-
toxic activities. Thus, induction of TNF-K is reduced
compared to enterobacterial lipid A [95].
5. Concluding remarks
The chemistry and immunobiology of chlamydial
lipopolysaccharide has seen remarkable progress in
the last decade. Still, important aspects such as the
structure, biosynthesis and endotoxicity of chlamy-
dial lipid A, the intriguing properties of the chlamy-
dial Kdo-transferases and the potential formation of
S-form LPS in embryonated eggs [96] will have to be
worked out. The presently completed sequencing of
the chlamydial genome will be of great value in this
respect in contributing to our knowledge on the
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pathogenicity and biology of this important micro-
organism.
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